Canaccord analyst Whitney Ijem raised the firm’s price target on Beam Therapeutics (BEAM) to $75 from $74 and keeps a Buy rating on the shares. The firm said BEAM’s 4Q25 earnings report was straightforward following the company’s early January strategic priorities announcement with two notable new announcements; a $500M financing agreement with Sixth Street and a new liver-targeted program, BEAM-304, for the treatment of PKU.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
- Beam Therapeutics price target raised to $47 from $45 at BofA
- Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
- Beam Therapeutics announces $500M financing facility
- Beam Therapeutics Secures $500 Million Credit Facility